These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18186957)

  • 1. Bevacizumab: optimal dose, schedule, and duration of therapy.
    Gandara DR; Sangha R; Davies AM
    Clin Lung Cancer; 2007 Nov; 8(9):522-3. PubMed ID: 18186957
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibodies to vascular endothelial growth factor in non-small cell lung cancer.
    Wakelee H
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S113-8. PubMed ID: 18520292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer.
    Bertino E; Villalona-Calero MA; Ross P; Grever M; Otterson GA
    Ann Thorac Surg; 2011 Feb; 91(2):640. PubMed ID: 21256341
    [No Abstract]   [Full Text] [Related]  

  • 4. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In focus: non-small cell lung cancer: E1505.
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):206-8. PubMed ID: 17519882
    [No Abstract]   [Full Text] [Related]  

  • 6. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
    Ramalingam S; Belani C
    Oncologist; 2008; 13 Suppl 1():5-13. PubMed ID: 18263769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
    Kanda S; Goto K; Shiraishi H; Kubo E; Tanaka A; Utsumi H; Sunami K; Kitazono S; Mizugaki H; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Hozumi H; Tamura T
    Ann Oncol; 2016 Dec; 27(12):2242-2250. PubMed ID: 27765756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
    Clément-Duchêne C; Krupitskaya Y; Ganjoo K; Lavori P; McMillan A; Kumar A; Zhao G; Padda S; Zhou L; Pedro-Salcedo MS; Colevas AD; Wakelee HA
    J Thorac Oncol; 2010 Nov; 5(11):1821-5. PubMed ID: 20881641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
    Reck M; von Pawel J; Zatloukal P; Ramlau R; Gorbounova V; Hirsh V; Leighl N; Mezger J; Archer V; Moore N; Manegold C
    J Clin Oncol; 2009 Mar; 27(8):1227-34. PubMed ID: 19188680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
    Soria JC
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155
    [No Abstract]   [Full Text] [Related]  

  • 12. [Bevacizumab in the first-line therapy of advanced NSCLC].
    Hasenöhrl N
    Wien Med Wochenschr; 2007; 157(21-22):576-8. PubMed ID: 18157597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.
    Mok TS; Hsia TC; Tsai CM; Tsang K; Chang GC; Chang JW; Sirisinha T; Sriuranpong V; Thongprasert S; Chua DT; Moore N; Manegold C
    Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():4-12. PubMed ID: 21585703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating novel agents with gemcitabine-based treatment of NSCLC.
    Treat J
    Lung Cancer; 2005 Oct; 50 Suppl 1():S8-9. PubMed ID: 16291433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in non-small cell lung cancer.
    Di Costanzo F; Mazzoni F; Micol Mela M; Antonuzzo L; Checcacci D; Saggese M; Di Costanzo F
    Drugs; 2008; 68(6):737-46. PubMed ID: 18416583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
    Mok T; Gorbunova V; Juhasz E; Szima B; Burdaeva O; Orlov S; Yu CJ; Archer V; Hilton M; Delmar P; Pallaud C; Reck M
    J Thorac Oncol; 2014 Jun; 9(6):848-55. PubMed ID: 24807156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of standard chemotherapy and targeted agents.
    Bareschino MA; Morgillo F; Ciardiello F
    J Thorac Oncol; 2007 May; 2(5 Suppl):S19-23. PubMed ID: 17457224
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.